On March 13th, RudaCure and Hanlim Pharmaceutical held an advisory meeting for Phase 2 clinical trials of their dry eye disease treatment, inviting 13 ophthalmology clinical experts.
At the advisory meeting held at the Mondrian Hotel, with the assistance of Hanlim Pharmaceutical's marketing department, 13 anterior segment ophthalmology professors from across the country were invited to share project descriptions and Phase 1 clinical trial progress for RCI001/HL262, and to receive advice for successfully conducting Phase 2 clinical trials.
We sincerely thank all the professors and Hanlim Pharmaceutical colleagues who attended, and we will do our best to achieve results that meet everyone's expectations.